Atherosclerosis
Volume 205, Issue 2 , Pages 385-390 , August 2009

Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community

  • Majd A.I. Mirza

      Affiliations

    • Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    • ,
  • Anders Larsson

      Affiliations

    • Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    • ,
  • Lars Lind

      Affiliations

    • Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    • ,
  • Tobias E. Larsson

      Affiliations

    • Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    • Department of Nephrology, Karolinska University Hospital, Stockholm, Sweden
    • Corresponding Author InformationCorresponding author at: Department of Medical Sciences, Uppsala University Hospital, Ing.70, 3 tr, UAS, 75185 Uppsala, Sweden. Tel.: +46 18 611 2657; fax: +46 18 500952.

Received 30 September 2008 ,Revised 28 November 2008 ,Accepted 5 January 2009.

References 

  1. Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis. 2004;43:572–579
  2. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938–942
  3. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol. 2003;14:S305–309
  4. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16:1788–1793
  5. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol. 2003;23:369–379
  6. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  7. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–435
  8. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500–6505
  9. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272–2279
  10. Fukagawa M, Nii-Kono T, Kazama JJ. Role of fibroblast growth factor 23 in health and in chronic kidney disease. Curr Opin Nephrol Hypertens. 2005;14:325–329
  11. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–592
  12. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol. 2005;25:2368–2375
  13. Flodin M, Jonsson AS, Hansson LO, Danielsson LA, Larsson A. Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m(2) from the cystatin C values in mg/L. Scand J Clin Lab Invest. 2007;67:560–567
  14. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002;87:4957–4960
  15. Imel EA, Peacock M, Pitukcheewanont P, et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2006;91:2055–2061
  16. Lind L, Sarabi M, Millgard J, et al. Methodological aspects of the evaluation of endothelium-dependent vasodilatation in the human forearm. Clin Physiol (Oxf, Engl). 1998;18:81–87
  17. Lind L, Pettersson K, Johansson K, et al. Analysis of endothelium-dependent vasodilation by use of the radial artery pulse wave obtained by applanation tonometry. Clin Physiol Funct Imaging. 2003;23:50–57
  18. Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  19. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491–497
  20. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731–1740
  21. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51
  22. Nagai R, Saito Y, Ohyama Y, et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci. 2000;57:738–746
  23. Saito Y, Yamagishi T, Nakamura T, et al. Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun. 1998;248:324–329

PII: S0021-9150(09)00009-4

doi: 10.1016/j.atherosclerosis.2009.01.001

Atherosclerosis
Volume 205, Issue 2 , Pages 385-390 , August 2009

Article Tools

* Image Usage & Resolution